What is GRI's relative strength rating?

GRI ranks at the 87th percentile over 1 month, 27th percentile over 3 months, 21th percentile over 6 months, 3th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is GRI in?

GRI is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is GRI in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). GRI benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

GRI currently shows a 20-day average daily range (ADR%) of 10.4%, a 90-day beta versus the S&P 500 of 0.08. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does GRI have a seasonal pattern?

TickerStance computes GRI's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what GRI has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did GRI last report earnings?

GRI most recently filed a 10-Q covering FY26 Q2 with the SEC on 2026-08-14. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.

GRI Bio, Inc. Common Stock (GRI) · RS 21

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, GRI Bio, Inc. Common Stock (GRI) has a 3-month relative strength percentile of 27 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 33. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 10.4%, relative volume 0.66×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month27pctile

6 month21pctile

1 year3pctile

Classic8IBD pctile

LDR25leadership

0 of 5 lenses lit · avg RS pctile 17

✓ADR%10.4%✓A/DA!RVOL0.66×!$ Vol$446K

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

§ Seasonality

10y · since 2023

Best monthOct on averageavg +34.82% · 33% win · n 3

Worst monthJan on averageavg -38.80% · 0% win · n 3

GRI monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	GRI Jan avg: -38.80% median: -39.88% win: 0% σ: 14.59% n: 3 2023-04-25 → 2026-07-31	GRI Feb avg: -32.88% median: -26.28% win: 0% σ: 15.50% n: 3 2023-04-25 → 2026-07-31	GRI Mar avg: -24.95% median: -10.20% win: 0% σ: 30.11% n: 3 2023-04-25 → 2026-07-31	GRI Apr avg: -27.65% median: -31.09% win: 0% σ: 19.06% n: 4 2023-04-25 → 2026-07-31	GRI May avg: -18.72% median: -19.93% win: 0% σ: 11.01% n: 4 2023-04-25 → 2026-07-31	GRI Jun avg: -24.62% median: -21.47% win: 0% σ: 20.31% n: 4 2023-04-25 → 2026-07-31	GRI Jul avg: -24.62% median: -18.79% win: 0% σ: 25.29% n: 4 2023-04-25 → 2026-07-31	GRI Aug avg: -29.90% median: -33.68% win: 33% σ: 36.75% n: 3 2023-04-25 → 2026-07-31 (current)	GRI Sep avg: 13.79% median: 22.05% win: 67% σ: 39.20% n: 3 2023-04-25 → 2026-07-31	GRI Oct avg: 34.82% median: -17.48% win: 33% σ: 93.89% n: 3 2023-04-25 → 2026-07-31	GRI Nov avg: -18.14% median: -22.15% win: 33% σ: 33.96% n: 3 2023-04-25 → 2026-07-31	GRI Dec avg: -34.49% median: -37.00% win: 33% σ: 54.47% n: 3 2023-04-25 → 2026-07-31

Evidence · 1 of 3

Receipts behind the read

1 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

87

3m

27

6m

21

1y

3

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline✓

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · GRI

Does the business back the chart?

SEC EDGAR · last filing 10-Q · FY26 Q2 · period end 2026-06-30

1

Fundamentals Growth Rank

How does growth rank vs. the universe?

vs. 4,480 ranked stocks · Sector rank 1

View fundamental leadership map

Laggard

Earnings

Are losses narrowing?

Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.

Loss narrowing

−$0.67—

24 Q3

−$49.16—

24 Q4

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
GRI
27RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

PLXProtalix BioTherapeutics, Inc. Common Stock21 GELSGelteq Limited Ordinary Shares21 BTMDBiote Corp. Class A Common Stock21 IBRXImmunityBio, Inc. Common Stock21

Public attention · GRI

Is the crowd watching?

48/ 100 · vs its own 90-day norm▼ 3 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float1.7Mshares

Shares out2.2Mshares

Market cap$3.9MNano Cap

FAQ

Frequently asked questions

What is GRI's relative strength rating?: GRI ranks at the 87th percentile over 1 month, 27th percentile over 3 months, 21th percentile over 6 months, 3th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is GRI in?: GRI is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is GRI in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). GRI benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is GRI?: GRI currently shows a 20-day average daily range (ADR%) of 10.4%, a 90-day beta versus the S&P 500 of 0.08. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does GRI have a seasonal pattern?: TickerStance computes GRI's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what GRI has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

GRI Bio, Inc. Common Stock (GRI) — Stance & relative strength

Lenses lit

Market backdrop

§ Seasonality

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?

§ Seasonality

GRI Bio, Inc. Common Stock (GRI) — Stance & relative strength

GRI is not confirmed as a leader. 27 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?